<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14. CLINICAL STUDIES <BR>               <BR>                  The use of single-agent XALKORI in the treatment of locally advanced or metastatic ALK-positive NSCLC was investigated in 2 multi-center, single-arm studies (Studies A and B). Patients enrolled into these studies had received prior systemic therapy, with the exception of 15 patients in Study B who had no prior systemic treatment for locally advanced or metastatic disease. In Study A, ALK-positive NSCLC was identified using the Vysis ALK Break-Apart FISH Probe Kit. In Study B, ALK-positive NSCLC was identified using a number of local clinical trial assays. The primary efficacy endpoint in both studies was Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Response was evaluated by the investigator and by an independent radiology review panel. Duration of Response (DR) was also evaluated. Patients received 250 mg of XALKORI orally twice daily. Demographic and disease characteristics for Studies A and B are provided in Table 4. <BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t4"><BR>                     <caption>Table 4: Demographic and Disease Characteristics in Studies A and B</caption><BR>                     <col width="70%" align="left" valign="top"/><BR>                     <col width="15%" align="center" valign="top"/><BR>                     <col width="15%" align="center" valign="top"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Lrule Rrule">Characteristics</th><BR>                           <th styleCode="Rrule">Study A<br/>N=136</th><BR>                           <th styleCode="Rrule">Study B<br/>N=119</th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Sex, n (%)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Male</td><BR>                           <td styleCode="Rrule">64 (47)</td><BR>                           <td styleCode="Rrule">59 (50)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Female</td><BR>                           <td styleCode="Rrule">72 (53)</td><BR>                           <td styleCode="Rrule">60 (50)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Age (years)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Median (range)</td><BR>                           <td styleCode="Rrule">52 (29&#8211;82)</td><BR>                           <td styleCode="Rrule">51 (21&#8211;79)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Race, n (%)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;White</td><BR>                           <td styleCode="Rrule">87 (64)</td><BR>                           <td styleCode="Rrule">74 (62)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Black</td><BR>                           <td styleCode="Rrule">5 (4)</td><BR>                           <td styleCode="Rrule">3 (3)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Asian</td><BR>                           <td styleCode="Rrule">43 (32)</td><BR>                           <td styleCode="Rrule">34 (29)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Other</td><BR>                           <td styleCode="Rrule">1 (1)</td><BR>                           <td styleCode="Rrule">8 (7)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">ECOG PS at baseline, n (%)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;0</td><BR>                           <td styleCode="Rrule">37 (27)</td><BR>                           <td styleCode="Rrule">41 (35)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;1</td><BR>                           <td styleCode="Rrule">74 (54)</td><BR>                           <td styleCode="Rrule">63 (53)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;2 &#8211; 3<footnote ID="table4a">Includes 1 patient with an ECOG PS of 1 at screening but was 3 at baseline.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">25 (18)</td><BR>                           <td styleCode="Rrule">15 (13)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Smoking status, n (%)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Never smoked</td><BR>                           <td styleCode="Rrule">92 (68)</td><BR>                           <td styleCode="Rrule">86 (72)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Former smoker</td><BR>                           <td styleCode="Rrule">39 (29)</td><BR>                           <td styleCode="Rrule">32 (27)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Current smoker</td><BR>                           <td styleCode="Rrule">5 (4)</td><BR>                           <td styleCode="Rrule">1 (1)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Disease stage, n (%)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Locally advanced</td><BR>                           <td styleCode="Rrule">9 (7)</td><BR>                           <td styleCode="Rrule">5 (4)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Metastatic</td><BR>                           <td styleCode="Rrule">127 (93)</td><BR>                           <td styleCode="Rrule">114 (96)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Histological classification, n (%)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Adenocarcinoma</td><BR>                           <td styleCode="Rrule">130 (96)</td><BR>                           <td styleCode="Rrule">116 (98)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Large cell carcinoma</td><BR>                           <td styleCode="Rrule">1 (1)</td><BR>                           <td styleCode="Rrule">1 (1)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Squamous cell carcinoma</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">1 (1)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Adenosquamous carcinoma</td><BR>                           <td styleCode="Rrule">3 (2)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Other</td><BR>                           <td styleCode="Rrule">2 (2)</td><BR>                           <td styleCode="Rrule">1 (1)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Prior systemic therapy for locally advanced or metastatic disease -- number of regimens, n (%)</td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;0</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">15 (13)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;1</td><BR>                           <td styleCode="Rrule">13 (10)</td><BR>                           <td styleCode="Rrule">34 (29)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;2</td><BR>                           <td styleCode="Rrule">37 (27)</td><BR>                           <td styleCode="Rrule">20 (17)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;3</td><BR>                           <td styleCode="Rrule">37 (27)</td><BR>                           <td styleCode="Rrule">17 (14)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;&#8805;4</td><BR>                           <td styleCode="Rrule">49 (36)</td><BR>                           <td styleCode="Rrule">33 (28)</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR>One hundred thirty-six patients with locally advanced or metastatic ALK-positive NSCLC from Study A were analyzed at the time of data cutoff. The median duration of treatment was 22 weeks. Based on investigator assessments, there was 1 complete and 67 partial responses for an ORR of 50% (95% CI: 42%, 59%). Seventy-nine percent of objective tumor responses were achieved during the first 8 weeks of treatment. The median response duration was 41.9 weeks.  <BR>                  One hundred nineteen patients with locally advanced or metastatic ALK-positive NSCLC were enrolled into Study B at the time of data cutoff. The median duration of treatment was 32 weeks. Based on investigator assessments, there were 2 complete and 69 partial responses for an ORR of 61% (95% CI: 52%, 70%). Fifty-five percent of objective tumor responses were achieved during the first 8 weeks of treatment. The median response duration was 48.1 weeks.<BR>                  Efficacy data from Studies A and B are provided in Table 5.<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t5"><BR>                     <caption>Table 5: Locally Advanced or Metastatic ALK-Positive NSCLC Efficacy Results from Studies A and B <footnote ID="table5a">Response as assessed by the Investigator.</footnote><BR>                     </caption><BR>                     <col width="54%" align="left" valign="top"/><BR>                     <col width="23%" align="center" valign="top"/><BR>                     <col width="23%" align="center" valign="top"/><BR>                     <thead><BR>                        <tr><BR>                           <th styleCode="Lrule Rrule">Efficacy Parameter</th><BR>                           <th styleCode="Rrule">Study A<br/>N=136</th><BR>                           <th styleCode="Rrule">Study B<br/>N=119</th><BR>                        </tr><BR>                     </thead><BR>                     <tfoot><BR>                        <tr><BR>                           <td colspan="3" align="left">+Censored values</td><BR>                        </tr><BR>                     </tfoot><BR>                     <tbody><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">Objective Response Rate (CR+PR)<footnote ID="table5b">One patient was not evaluable for response in Study A; 3 patients were not evaluable for response in Study B.</footnote> [% (95% CI)]</td><BR>                           <td styleCode="Rrule">50% (42%, 59%)</td><BR>                           <td styleCode="Rrule">61% (52%, 70%)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Number of Responders</td><BR>                           <td styleCode="Rrule">68</td><BR>                           <td styleCode="Rrule">71</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">Duration of Response<footnote ID="table5c">Preliminary estimate using Kaplan-Meier method.</footnote> [Median (range) weeks]</td><BR>                           <td styleCode="Rrule">41.9 (6.1+, 42.1+)</td><BR>                           <td styleCode="Rrule">48.1 (4.1+, 76.6+)</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>               <BR><BR><BR><BR>               <BR>            <BR>         </P></DIV></HTML>